On September 13, 2025, the “China-US Biotech + RWA Investment Summit”—a core event under the BIOHK2025 Hong Kong International Biotechnology Forum & Exhibition—was successfully held at the Hong Kong Convention and Exhibition Centre. As one of the co-hosts, MINAX Global Brand Exchange deeply participated in the summit’s preparation and core sessions. With the “Web3+RWA” innovative model as the key driver, it promoted in-depth connection between the biotech industry and digital capital in China, the US, and the Asia-Pacific region, helping Hong Kong build a global highland for digital investment in biotech.

The summit was hosted by the Hong Kong Biotechnology Association, co-hosted by the China-US Healthcare Industry Investment & M&A Alliance, Hong Kong Digital Asset Listed Companies Association, and MINAX Global Brand Exchange, and co-organized by institutions including the Association for Corporate Growth (ACG) and the International Professional Committee of All-China Mergers & Acquisitions Association. It gathered 130 heavyweight guests, including 50 heads of well-known investment institutions, 30 executives of large biotech enterprises, and 20 experts in the Web3+RWA field. Focusing on the integrated development of AI, Web3, RWA, and biotech, the summit built a high-end platform for industrial cooperation and capital connection.
Image

As a core force driving the integration of biotech and RWA, the MINAX team elaborated on the transformative significance of RWA to the biotech industry from multiple dimensions, including technical logic, industrial value, and practical paths.

Mr. Gong Fangxiong pointed out that against the backdrop of China-US decoupling, China’s biotech sector is gradually going global, which is a very encouraging trend from the perspective of the capital market. The biotech industry has long suffered from the pain point of “financing mismatch”—it needs funds most in the early R&D stage but is unable to go public due to the lack of cash flow and profitability; however, when profitability stabilizes, its demand for capital decreases. Previously, the innovation of listing rules promoted by Charles Li at the Hong Kong Stock Exchange opened an IPO channel for biotech enterprises without cash flow or profitability. RWA (Real-World Asset tokenization) provides a new opportunity for the biotech sector to go global. It serves as a bridge connecting Web2 and Web3, the real world and the blockchain world, similar to the integrating role of stablecoins. In the biotech field, IP and data are important real-world assets and fall into the category of brand assets, and MINAX is focusing on the digital assetization of brand RWA.

Mr. Danny Deng stated that the blockchain industry can only develop in the long run by taking root in the real economy and operating legally and compliantly. His team has laid the foundation for building the MINAX Brand Exchange by integrating past resources, experience in blockchain transformation, and experience in power system reform. The core of the brand exchange is to convert brand assets into RWA categories, and IP, data, and communities in the biomedical and healthcare fields are all convertible. According to a joint forecast by Boston Consulting Group (BCG) and ADDX, the global RWA market size will reach US$16.1 trillion by 2030, with the medical sector accounting for 1/5. The market is developing rapidly—for example, Dubai plans to put US$1.5 trillion in assets on the chain. RWA assets in the biomedical and healthcare fields that can be brand-digitized cover six categories, including intellectual property, R&D pipelines, cash flow, physical assets, brand assets, and data & equity assets. There are already cases such as Huajian Medical and Guofu Quantum, and MINAX has also launched projects such as agarwood tree assets and TCM chain brands, with a single project potentially reaching a scale of US$10 billion. In addition, MINAX has built a full RWA chain of “domestic authorization – Hong Kong confirmation – offshore issuance – global trading”. It is exploring ways to reduce RWA costs, promoting cooperation with regulators of various countries, accelerating the listing and issuance process of RWA assets, and realizing industry standardization.

Ms. Wang Zining has over 20 years of experience in traditional investment banking. Having visited a large number of TCM enterprises, she is well aware of the industry’s pain points and resilience, and has been committed to building characteristic investment channels for China’s biomedical industry. She revealed that a professional healthcare fund has been launched in the Middle East, with procedures basically completed. In the past, Middle Eastern capital mainly focused on “buying globally”; now, it has shifted to national construction and will provide preferential policies and funds for high-quality biotech technologies settled in the UAE, Saudi Arabia, Oman and other countries, but also requires the other party to drive investment in China to form two-way cooperation. This Middle Eastern healthcare fund plans to focus on brand building, select investment targets from platforms like MINAX, and design investment directions accurately to help China’s biomedical industry connect with Middle Eastern capital and promote industrial development.

MINAX Global Brand Exchange reached strategic cooperation with the Hong Kong Web3 Standardization Association and the China-US Healthcare Industry Investment & M&A Alliance. Mr. Danny Deng, CEO of MINAX Global Brand Exchange, signed the cooperation agreement as the representative, together with Li Ming, Executive President of the Hong Kong Web3 Standardization Association, and Wang Ping, Representative of the China-US Healthcare Industry Investment & M&A Alliance.

With “Web3+RWA” technology as the core, this three-party cooperation plans to integrate high-quality global biotech resources, convert core industrial assets such as patented technologies, R&D achievements, and medical equipment into digital RWA products, open up an efficient channel for connecting industry and capital, and help Hong Kong achieve its positioning as a “global digital investment base for biotech”.

Dr. Tang Yiduan stated at the summit that the Digital Asset and Innovation Research Center of Hong Kong Polytechnic University provides key technical support. The university has been deeply engaged in the blockchain field for 10 years, leading the world in the number of blockchain-related papers published. It has received RMB 100 million in funding from Ant Group for R&D and has cooperated with a number of listed companies to explore the construction of industrial-level RWA platforms. Dr. Tang Yiduan said that the center is accelerating “knowledge transfer” to promote blockchain technology from theory to industrial practice. MINAX has become the core carrier for the implementation of scientific research achievements—through standardized services, it enables the digitalization of biotech assets to be “cost-reducing, efficiency-enhancing, and compliant”, laying a technical foundation for subsequent projects.

At the “Biotech RWA Launch Ceremony” session of the summit, five high-quality biotech projects recommended by MINAX Global Brand Exchange successively completed roadshows, covering five fields: innovative TCM drugs, agarwood health preservation, cancer screening, deep processing of agricultural products, and genetic health management. All projects rely on the MINAX brand RWA system to promote asset digitalization and industrial development.

Yuanda Liu’s, a 160-year-old innovative TCM enterprise, focuses on its national patented product “Qingfei Sanjie Granules”, which has been clinically proven to reduce the risk of post-COVID lung nodule transformation. Relying on MINAX, it has converted its brand’s historical accumulation and patented technologies into RWA assets, realizing the digital upgrading of the traditional TCM brand. An exclusive listing bell-ringing ceremony was also held on site, marking the official listing of the brand’s RWA assets on the trading platform.

Chaoxianggu owns China’s largest 6,000-mu first-generation Aquilaria sinensis base, with 1.2 million agarwood trees valued at a conservative RMB 50,000 each, totaling RMB 60 billion in physical assets. Its agarwood products, with core effects such as “enhancing yang energy, repairing respiratory function, and soothing nerves to aid sleep”, have collaborated with Uni-President Group to develop tea drinks and launched atomized products in 4,000 hospitals. Through the MINAX system, the enterprise has digitized the physical assets of the agarwood base, product R&D data, and brand. Meanwhile, leveraging Middle Eastern market demand and Dubai’s financial license, it promotes the global circulation of brand digital assets.

Xiayunyun Technology focuses on the clinically unmet need of at-home non-invasive screening for “interval breast cancer”. It has collaborated with the National Health Commission to formulate the world’s first at-home screening standard, launched the world’s first interactive breast cancer insurance, obtained special approvals from the National Health Commission and the China Banking and Insurance Regulatory Commission, and completed clinical registration.

As a global leader in deep processing of lemons, Mengtai Biotechnology controls 90% of the lemon product supply chain, owns the world’s first 479-meter-long processing production line, and its small-molecule pectin technology can reduce industry costs by 50% and improve quality by 1.2 times. It leads the formulation of 14 industry standards. Through MINAX, it converts lemon supply chain assets, production technology patents, and product brand value into RWA, helping characteristic agricultural industries connect with digital capital efficiently.

iOmica Genomics builds a personal health management system with multi-omics (genomics, proteomics, etc.) + AI, launching a “body passport” and a 24-hour AI health assistant that can predict diseases such as heart disease and cancer 3-5 years in advance. It plans to reduce testing costs to cover the C-end market, and its 1.0 version will soon be launched in a 50,000-client physical examination center.

The successful holding of the BIOHK2025 China-US Biotech + RWA Investment Summit not only demonstrates MINAX’s capabilities in resource integration and ecosystem construction in the biotech RWA field but also promotes RWA to become a key link connecting global capital and the biotech industry. In the future, with the continuous improvement of MINAX’s full-chain services and the in-depth participation of global capital, biotech digital investment will serve as a fulcrum to drive a dual leap in industrial innovation and capital efficiency.